The Clinically Tested Gardos Channel Inhibitor Senicapoc Exhibits Antimalarial Activity

ABSTRACT Senicapoc, a Gardos channel inhibitor, prevented erythrocyte dehydration in clinical trials of patients with sickle cell disease. We tested the hypothesis that senicapoc-induced blockade of the Gardos channel inhibits Plasmodium growth. Senicapoc inhibited in vitro growth of human and primate plasmodia during the clinical blood stage. Senicapoc treatment suppressed P. yoelii parasitemia in vivo in C57BL/6 mice. The reassuring safety and biochemical profile of senicapoc encourage its use in antimalarial development.

[1]  S. Alper,et al.  N-ethylmaleimide activates a Cl(-)-independent component of K(+) flux in mouse erythrocytes. , 2013, Blood cells, molecules & diseases.

[2]  K. Ataga,et al.  Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso‐occlusive crises in patients with sickle cell disease: a phase III randomized, placebo‐controlled, double‐blind study of the gardos channel blocker senicapoc (ICA‐17043) , 2011, British journal of haematology.

[3]  F. Lang,et al.  Functional significance of the intermediate conductance Ca2+-activated K+ channel for the short-term survival of injured erythrocytes , 2010, Pflügers Archiv - European Journal of Physiology.

[4]  K. Chandy,et al.  The functional network of ion channels in T lymphocytes , 2009, Immunological reviews.

[5]  Kami Kim,et al.  Plasmodium falciparum: growth response to potassium channel blocking compounds. , 2008, Experimental parasitology.

[6]  K. Ataga,et al.  Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. , 2008, Blood.

[7]  E. Novellino,et al.  Clotrimazole scaffold as an innovative pharmacophore towards potent antimalarial agents: design, synthesis, and biological and structure-activity relationship studies. , 2008, Journal of medicinal chemistry.

[8]  G. Rigdon,et al.  Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. , 2008, Journal of medicinal chemistry.

[9]  K. Ataga,et al.  Dose‐Escalation Study of ICA‐17043 in Patients with Sickle Cell Disease , 2006, Pharmacotherapy.

[10]  C. Brugnara,et al.  Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. , 2003, Journal of pediatric hematology/oncology.

[11]  J. Stocker,et al.  ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. , 2003, Blood.

[12]  T. Tiffert,et al.  Potent antimalarial activity of clotrimazole in in vitro cultures of Plasmodium falciparum. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Kiaran Kirk,et al.  Cell volume control in the Plasmodium-infected erythrocyte. , 2004, Trends in parasitology.